Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases

被引：0
|
作者：
Siddharth Singh
Herbert C. Heien
Lindsey Sangaralingham
Nilay D. Shah
William J. Sandborn
机构：
[1] University of California San Diego,Division of Gastroenterology, Department of Medicine
[2] University of California San Diego,Division of Biomedical Informatics, Department of Medicine
[3] Mayo Clinic,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
[4] Mayo Clinic,Division of Health Care Policy and Research, Department of Health Services Research
来源：
Digestive Diseases and Sciences | 2022年 / 67卷
关键词：
Cancer; Safety; Choice; Colitis; Biologics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2510 / 2516
页数：6
相关论文
共 50 条
  • [41] Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study
    Rousset, Laurie
    de Masson, Adele
    Begon, Edouard
    Villani, Axel
    Battistella, Maxime
    Rybojad, Michel
    Jachiet, Marie
    Bagot, Martine
    Bouaziz, Jean-David
    Lepelletier, Clemence
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (04) : 1141 - 1143
  • [42] Targeting tumor necrosis factor-α in inflammatory bowel disease:: why, how, and when?
    Hommes, DW
    van Deventer, SJH
    CURRENT OPINION IN GASTROENTEROLOGY, 2003, 19 (04) : 350 - 357
  • [43] Initiation of Tumor Necrosis Factor Antagonists and Risk of Fractures in Patients With Selected Rheumatic and Autoimmune Diseases
    Kawai, Vivian K.
    Grijalva, Carlos G.
    Arbogast, Patrick G.
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Delzell, Elizabeth
    Chen, Lang
    Ouellet-Hellstrom, Rita
    Herrinton, Lisa
    Liu, Liyan
    Mitchell, Edward F., Jr.
    Stein, C. Michael
    Griffin, Marie R.
    ARTHRITIS CARE & RESEARCH, 2013, 65 (07) : 1085 - 1094
  • [44] Utilizing Natural Language Processing to Examine the Risk of Arthralgia Between Vedolizumab and Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease
    Lin, Tzu-Chieh
    Cai, Tianrun
    Kane-Wanger, Gwendolyn
    Cagan, Andrew
    Murphy, Shawn N.
    Ananthakrishnan, Ashwin
    Liao, Katherine P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 35 - 36
  • [45] Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease
    Peyrin-Biroulet, Laurent
    Van Assche, Gert
    Gomez-Ulloa, David
    Garcia-Alvarez, Laura
    Lara, Nuria
    Black, Chris M.
    Kachroo, Sumesh
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (01) : 25 - +
  • [46] Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists
    Swart, Reinout M.
    van Ingen, Jakko
    van Soolingen, Dick
    Slingerland, Rob
    Hendriks, Willem D. H.
    den Hollander, Jan G.
    EMERGING INFECTIOUS DISEASES, 2009, 15 (10) : 1700 - 1701
  • [47] Tumor necrosis factor-α antagonists: Side effects and their management
    Dogra, Sunil
    Khullar, Geeti
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2013, 79 : S35 - S46
  • [48] Risk of Solid Organ and Hematological Malignancy in Patients With Inflammatory Bowel Diseases
    Kappelman, Michael
    Farkas, Dora K.
    Erichsen, Rune
    Pedersen, Lars
    Sandler, Robert S.
    Baron, John A.
    Sorensen, Henrik T.
    GASTROENTEROLOGY, 2011, 140 (05) : S41 - S41
  • [49] Malignancy Outcomes in Inflammatory Bowel Disease Patients on Immune Modulators and Anti-Tumor Necrosis Factor Therapy
    Patel, Umangi
    Lichtenstein, Gary
    Scott, Frank
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S484 - S484
  • [50] Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
    Olesen, Caroline Meyer
    Coskun, Mehmet
    Peyrin-Biroulet, Laurent
    Nielsen, Ole Haagen
    PHARMACOLOGY & THERAPEUTICS, 2016, 159 : 110 - 119
12345